Our Top Stories from this Week in Healthcare
Insights - The talk of a bubble in biotech seems to have subsided (temporarily, no doubt), and the sector-tracking iShares Nasdaq Biotech ETF (IBB) has continued higher … Continue Reading
Read NowRecap
A Heavy Dose of M&A this Week in Healthcare
Uh oh. Bubble Talk is Back in Biotech
Recap - Healthcare stocks were routed early this week, falling 10% (based on the NASDAQ Biotech Index) before a bounce from mid-week into Friday. The similarities to … Continue Reading
Read NowA Roundup of our Top Stories in Healthcare from the Week
Another Five Days of Biotech Stocks GRINDING Along
Recap - No one has the exact answer, but Mr. King’s post-JP Morgan musings from earlier this year seem relevant yet again. As of Friday’s close, the S&P 500 is actually down year-to-date, while the biotechnology sector is up an impressive 14%, as measured by the IBB. The two have clearly diverged, and it almost seems that investors are fleeing to biotechnology for safety. That’s quite a departure from years past.
Read Now